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Background: Hepatitis B virus is one of the main factors causing acute and chronic 
hepatitis and hepatocellular carcinoma. Among others, healthcare workers are at the 
highest risk for exposure to hepatitis B virus. Vaccination against hepatitis B virus is one 
of the protective strategies but anti-HBs titer will be reduced in the sera of vaccinated 
people after some time. The aim of this study was to determine the titer of anti-HBs in the 
sera of vaccinated medical staffs in three consecutive years since administration of the last 
dose of hepatitis B vaccine. 
Materials and Methods: This study was carried out on 90 Omidvar Hospital (Lar, Iran) 
medical staffs that had passed 3-4 months since the administration of the last dose of 
hepatitis B vaccine. All sera samples were tested for anti-HBs in an ELISA method. 
Finally, statistical analysis was performed using SPSS-16 software. 
Results: This study was conducted in duration of 3 consecutive years on 90 medical staffs 
including 14.44% lab technicians, 10% obstetricians, 43.35% nurses, 6.665% specialists, 
5.55% general practitioners and 20% maid staffs. While HBs Ab titer was measured as 
87.7% (>100 mIU/ml) in the first year elapsed since the last dose of hepatitis B 
vaccination, it had been decreased to 55.4% after 3 years. 
Conclusion: The results showed that re-vaccination of the medical staffs is quite necessary 
as anti-HBs titer had been decreased after 3 years and the desired immune response was 
seen only in 55.4% of the medical staffs. 
Copyright © 2013 Zahedan University of Medical Sciences. All rights reserved. 
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         Introduction 
epatitis B infection as one of the major health 
problems is responsible for chronic hepatitis and 
hepatocellular carcinoma [1]. According to the 
World Health Organization (WHO), 367 million people 
worldwide are suffering from hepatitis B and 1 million 
people die each year because of the complications of this 
disease [1, 2].  
According to the reports, 2-3% of the Iranian 
populations have been infected with hepatitis B virus, out 
of which 70-80% have been diagnosed as chronic 
hepatitis B [3, 4]. Those who are exposed to the blood 
samples are at high risk of acquiring infections to this 
virus. According to the reports of CDC (Center for 
Disease Control) every year 100-200 healthcare workers 
die as a result of hepatitis B infections [5]. Exposure of 
un-vaccinated medical staffs to the blood of infected 
patients through contaminated needles has caused 6-30% 
hepatitis B outbreak among these medical staffs. Medical 
staffs infection to the hepatitis B was reported as 0.4-
1.6% in America, 0.2-1.2% in Europe and 0.6-1.6% in 
Iran per year [6-8].  
With medical staffs being aware of hepatitis B 
transmission ways, destroying contaminated needles and 
most importantly by vaccination of those who are at 
increased risk of exposure to hepatitis B virus, the 
possibility of the occupational HBV transmission will be 
reduced dramatically. Administration of the hepatitis B 
vaccine will result in the appearance of anti-HBs within 
the bloodstream at a titer of 79-90%. It should be noted 
that increasing anti-HBs titer up to >10 mIU/ml results in 
protection against hepatitis B for the whole life [9-11]. 
Recent studies on antibody production by medical staffs 
in response to hepatitis B vaccination showed increased 
titer of hepatitis B antibody among medical staffs of 
Mazandaran (64.5%) [8], Kermanshah (69.6%) [12], 
Shahr-e-Kord (86.3%) [13] and Tehran (70.6%) [14]. All 
over the world, the prevalence of hepatitis B is classified 
as low prevalence (≤2%), intermediate prevalence (2-7%) 
and high prevalence (≥7%). In Iran, the prevalence of 
hepatitis B is 1.5-6.5% which has placed this country 
among intermediate prevalence groups [15]. 
Despite several studies, the titer of antibody which is 
produced in response to hepatitis B vaccination is not 
enough to give the vaccinated individuals long-time 
protection against this disease, a feature that is quite 
necessary for the health workers who are at increased risk 
for exposure to hepatitis B. According to numerous 
studies, the variation of the antibody titer in different 
individuals depends on their age, sex, smoking and 
exposure to the individuals with hepatitis B or liver 
diseases [16-18]. The aim of this study was to determine 
the titer of serological anti-hepatitis B surface antigen 
(anti-HBs) in the vaccinated medical staffs in three 
consecutive years. 
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Materials and Methods 
 
This study was conducted in a descriptive-analytic way 
on 90 Omidvar hospital (Lar, Iran) medical staffs who had 
passed three criteria for our study: completing the 
administration of hepatitis B, 3 dose series vaccine in 
2008, 3-4 months passing since receiving the last dose of 
vaccine and availability of information regarding medical 
staffs srea anti-HBs titer since the last dose of vaccination 
in 3 consecutive years of 2009, 2020 and 2011. 
Questionnaires regarding demographic information, date 
of 3 dose series vaccination, diseases history (hepatitis, 
diabetes) and smoking and drinking status were filled out 
by all the cases of this study and the accuracy of their 
information was checked with their personnel files 
available in the hospital archives. This study was 
completed adhering to the ethical aspects form Helsinki 
convention and was approved by Shiraz University of 
Medical Science Ethics Committee.  
All the cases were given the consent letter to be signed 
and patient information was kept private and secure. Five 
ml of venous blood were taken from each case, the sera 
was isolated, labeled with secret numbers and finally kept 
at -20 °3TC for the future analysis. The titer of anti-hepatitis 
B surface antigen (anti-HBs) was measured in an ELISA 
method making use of commercial hepatitis B ELISA kits 
(DiaplusInc, USA).  
3TDescriptive statistical analysis was carried out using 
SPSS-16 software. Chi-square test, one way ANOVA 
test, Levene's test 0T3Tand 0T3TPearson's correlation coefficient 0T3T 
were utilized for statistical analysis tests. p-value 0T≤0.05 
was considered as significant level. To interpret the 
results according to the available sources, hepatitis B 
surface antibody titer of ≤10 mIU/ml was classified as 
weak response, antibody titer of 10-100 mIU/ml was 
considered as adequate response and antibody titer of 




This study was conducted in 3 consecutive years of 
2009, 2020 and 2011 on the titer of anti-HBs in the sera 
of 90 medical staffs of Omidvar hospital (Lar, Iran) 
including 66 (73.33%) women and 24 (26.66%) men with 
the age range of 22-53 years old and the mean age of 
34.90±8.66. No significant association was seen between 
the age and sex of the cases in an ANOVA test. The cases 
of this study included 14.44% (11 women, 2 men) lab 
technicians, 10% (5 women) obstetricians, 43.33% (34 
women, 5 men) nurses, 6.66% (1 women, 5 men) 
specialist, 5.55% (2 women, 3 men) general practitioner 
and 20% (9 women, 9 men) maid staffs. There was a 
considerable association between age range and job 
groups (p=0.004) (Table 1) and sex and job groups 
(p=0.01) in a chi-square test.  
Measuring anti-HBs in 3 consecutive years in the cases 
of this study showed 3 individuals (3.3%) with the titer of 
≤10 mIU/ml (weak response), 8 individuals (8.9%) with 
the titer of 10-100 mIU/ml (adequate response) and 79 
individuals (87.8%) with the titer of ≥100 mIU/ml 
(desired response) in the first year of the study while it 
had been decreased to 22 individuals (24.4%) with the 
titer of ≤10 mIU/ml (weak response), 19 individuals 
(21.1%) with the titer of 10-100 mIU/ml (adequate 
response) and 49 individuals (54.4%) with the titer of 
≥100 mIU/ml (desired response) in the third year of the 
study. 
 There was a significant association (p=0.001) between 
increasing the time elapsed since the last vaccination and 
decreasing anti-HBs titer in a t-test. Accordingly, there 
was a meaningful association (p=0.002) between 
decreasing anti-HBs titer and sex of the participants in an 
ANOVA test. The results showed more decline in desired 
immune response (≥100 mIU/ml) in women compared to 
the men so that it had been decreased from 86.36% to 
46.96% in women group and from 91.46% to 75% in men 
group. There was a significant association (p=0.001) 
between decreasing the antibody titer and the age range of 
the individuals so that a prominent decline in antibody 
titer was observed by increasing the age of the 
participants. Desired immune response among individuals 
above 40 years old in the first and third years of the study 
was reported as 86.36% (19 individuals) and 45.45% (10 
individuals), respectively, which shows a significant 
association (p=0.002) between increasing the age and 
decreasing anti-HBs titer. 
According to the results, the level of desired response 
among different job groups of this hospital during 3 
consecutive years had been decreased as follows: lab 
technicians (from 92.30% to 61.54%), obstetricians (from 
100.0% to 44.44%), nurses (from 84.64% to 46.15%) and 
maid staffs (from 83.33% to 55.55%). As it is shown in 
tables 2-4, there was a decrease in the amount of desired 
titer (≥100 mIU/ml) during 3 consecutive years so that the 
titer amount of 87.77% in the first year since receiving the 
last dose of vaccination had been decreased to 55.55% in 
the third year of the study. 
The desired antibody titer among participants of 
different age ranges during these 3 consecutive years of  
this study had been decreased as follows: individuals of 
20-30 years old (from 28% to 21%), individuals of 31-40 
years old (from 32% to 18%) and  individuals of 41-50 
years old (from 13% to 6%). A downturn change in 
desired antibody titer (≥100 mIU/ml) was seen among 
different sex groups by increasing the time elapsed since 
the last dose of vaccination, too. 
 
Table 1. Absolute frequency and percentage of the age range in different job groups of the study population  
 
Age(year)  Lab technician  (%)  Obstetrician  (%)  Nurse  (%)  Specian (%) General practitioner  (%)  Maid staff  (%)  Total  (%)  
20-30 8(8.88) 1(1.11) 16(17.77) 0(0) 3(3.33) 4(4.44) 32 (35.55) 
31-40 3(3.33) 7(7.78) 15(16.66) 4(4.44) 1(1.11) 6(6.66) 29(32.22) 
41-50 2(2.22) 1(1.11) 7(7.77) 1(1.11) 0(0) 4(4.44) 15(16.66) 
50> 0(0) 0(0) 1(1.11) 1(1.11) 1(1.11) 4(4.44) 7(7.77) 
Total(%) 13(14.44) 9(10) 39(43.33) 6(6.66) 5(5.55) 18(20) 90(100) 
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Table 2. Absolute frequency and percentage of anti-HBs titer in different job groups of the study population (2009) 
 


















Ab titer of ≤10 mIU/ml 1(7.69) 0(0) 2(5.12) 0(0) 0(0) 0(0) 3(4.45) 0(0) 
Ab titer between 10-100 
mIU/ml 
0(0) 0(0) 4(10.24) 0(0) 1(20) 3(16.66) 6(9.09) 2(8.33) 
Ab titer of ≥100 mIU/ml 12(92.30)  9(100) 33(84.63)  6(100) 4(80) 15(83.33) 57(86.66)  22(91.66) 
Total (%) 13(100)  9(100) 39(100) 6(100) 5(100) 18(100) 66(100) 24(100)  
 
Table 3. Absolute frequency and percentage of anti-HBs titer in different job groups of the study population (2010) 
 
 
Table 4. Absolute frequency and percentage of anti-HBs titer in different job groups of the study population (2011) 
 



















Ab titer of ≤10 mIU/ml 2(15.38) 4(44.44) 11(28.20) 1(16.66) 1(20) 3(16.66) 19(28.87) 3(12.5) 
Ab titer between 10-100 
mIU/ml 
3(23.07) 1(11.11) 10(25.64) 0(0) 0(0)  5(27.77) 16(24.24) 3(12.5) 
Ab titer of ≥100 mIU/ml 8(61.54) 4(44.44)  18(46.15) 5(83.33) 4(80) 10(55.55) 31(46.96) 18(75) 




Dermal-mucosal infection in the individuals who are at 
high risk of exposure to the blood and body fluids is 
accounted for the transmission of many serious diseases 
such as hepatitis B, hepatitis C and HIV. In developing 
countries hepatitis B as a dangerous viral disease has been 
assigned a big portion of their health budget to itself. 
Vaccination of the individuals who are at high risk of 
blood infections, such as healthcare workers is considered 
as one of the most effective ways to prevent this disease. 
Several factors including sex, age, body mass, smoking 
and the time elapsed since receiving the last dose of 
vaccination can affect protection against this disease [12-
13]. While in the first year since the last dose of 
vaccination antibody titer of ≤10 mIU/ml (weak response) 
was reported in 3.33% of the individuals, it had been 
increased to 23.33% of the individuals in the third year of 
the study. In fact 23.33% of the individuals were lacking 
the protective immune response in the third year of the 
study. According to our results, antibody titer of 77% is 
considered as the protective antibody titer which is 
consistent with the results of Jahanbakhsh et al. (Shahr-e-
Kord), Averhoff et al. (America) and Savadkoohi et al. 
who had considered antibody titer of 76% as the 
protective antibody titer in their investigations [12, 21]. 
Studying on the medical staffs of Tohid hospital (Iran) in 
2001, Rahimi et al. have found a significant association 
between the duration of the time elapsed since the last 
dose of vaccination and anti-HBs titer [23]. According to 
our results, there was a meaningful association between 
the titer of antibody and sex and age of the individuals so 
that the titer of antibody had been decreased by increasing 
the participant’s age. This result was consistent with those 
of other investigations [14, 21, 24, 25]. There was a 
significant difference in the amount of immune response 
between women and men groups. While the weak 
immune response was reported as 4.55% in women and 
0.0% in men in the first year since the last dose of 
vaccination, it had been increased to 28.77% in women 
and 12.5% in men after 3 years. Our results were not 
consistent with the results of other studies in Tabriz and 
Yazd in which the amount of immune response in women 
was greater than men [26-27]. Getting more immune 
response in women in the above studies could be the 
result of involving more women cases including nurses 
and obstetricians who are at high risk of exposure to the 
blood. Unlike our investigation, the study results of Perera 
et al at university of Michigan and Azadi et al at 
University of Tehran showed no association between the 
sex of the participants and the amount of immune 
response [28-30]. The desired immune response in 3 
consecutive years of 2009, 2010 and 2011 was reported as 
86.36%, 56.06% and 46.97%, respectively; in women 
group of 66 individuals and as 91.67%, 66.67% and 75%, 
respectively, in men group of 24 individuals. The amount 
of immune response in individuals under 40 years old was 
greater than that of individuals above 40 years old. 
Statistically, there was a meaningful association between 
increasing the age of the individuals and decreasing the 
antibody titer so that the amount of the desired response 
had been decreased from 66.66% (60 individuals) to 
43.33% (39 individuals) in the first year since the last 
dose of vaccination, which was in accordance with the 
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General practitioner   
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  N(%) 
Ab titer of ≤10 mIU/ml 4(30.76) 3(33.34) 10(25.64) 1(16.66) 1(20) 0(0) 17(25.75) 2(8.33) 
Ab titer between 10-100 
mIU/ml 
0(0) 2(22.22) 7(17.94) 1(16.66) 3(60) 5(27.77) 12(18.18) 6(25) 
Ab titer of ≥100 mIU/ml 9(69.23) 4(44.44) 22(56.41) 4(66.66) 1(20) 13(72.22) 37(56.06) 16(66.66) 
Total (%) 13(100) 9(100) (100)39  (100)6 5(100) 18(100) 66(100) 24(100) 




results of the other studies [31-33]. The result of 
monitoring immune responses in all 90 vaccinated 
participants in the first and third years of the study was as 
follows: weak immune response [3.33% (3 individuals) in 
the first year and 24.44% (22 individuals) in the third 
year]; adequate immune response [8.88% (8 individuals) 
in the first year and 21.11% (19 individuals) in the third 
year] and  desired response [87.77% (79 individuals) in 
the first year and 54.44% (49 individuals) in the third 
year]. While comparing our results with those of 
Kordestan [34] Shahr-e-Kord [35] and America [36] 
showed a weaker immune response to HBs vaccine, our 
results were consistent with those of Gorgan [37] and 
Kermanshah [38] in which 27.3% of the participants 
showed weak immune response (Ab titer of ≤10 mIU/ml). 
While the titer of anti HBs in the vaccinated medical 
staffs of this study had been at desired level in the first 
year since the last dose of vaccination, it had been 
decreased to the adequate level in most of the cases after 
some time. Several factors including sex, age and the time 
elapsed since receiving the last dose of vaccination can 
affect this decline process. Passing more years since the 
vaccination, the titer of anti-HBs in most of the 
vaccinated medical staffs will be decreased to the weak 
level, a time which makes re-vaccination quite requisite. 
This investigation underscores the importance of close 
monitoring of the performance of the infection control 
systems in health care facilities and further attention of 
the concerned authorities to the health of the medical 
staffs that are at the highest risk. Similar investigations 
regarding the effect of duration of the elapsed time on the 
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